Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30049355 | 0.87 | CYP1A2 (0.32) | CYP1A2CYP2C9CYP2C19KMT2A | |
| SCHEMBL25217957 | 0.82 | CYP1A2 (0.30) | CYP1A2CYP2C9CYP2C19KMT2A | |
| SCHEMBL30835179 | 0.76 | ABCB1 (0.35) | — | |
| SCHEMBL31235387 | 0.74 | PKM (0.30) | — | |
| SCHEMBL25247825 | 0.74 | L3MBTL1 (0.36) | CYP1A2CYP2C9CYP2C19KMT2A | |
| SCHEMBL25601605 | 0.73 | — | — | |
| SCHEMBL30254311 | 0.73 | — | — | |
| SCHEMBL30049924 | 0.73 | — | — | |
| SCHEMBL1188874 | 0.72 | KMT2A (0.36) | CYP1A2CYP2C9CYP2C19KMT2ACA1 | |
| SCHEMBL25402806 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240300980-A1 | HETEROCYCLIC COMPOUNDS AS KRAS INHIBITOR, AND PREPARATION THEREFOR AND USE THEREOF IN TREATMENT | SHANGHAI KECHOW PHARMA, INC. (CN) | 2024-09-12 | — | — | US | disclosed |
| CN-117813306-A | Heterocyclic compounds as KRAS inhibitors, their preparation and therapeutic use | 上海科州药物研发有限公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2022247760-A1 | HETEROCYCLIC COMPOUNDS AS KRAS INHIBITOR, AND PREPARATION THEREFOR AND USE THEREOF IN TREATMENT | 上海科州药物研发有限公司 | 2022-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300980-A1 | HETEROCYCLIC COMPOUNDS AS KRAS INHIBITOR, AND PREPARATION THEREFOR AND USE THEREOF IN TREATMENT | KRAS, NRAS, HRAS | CYP1A2 2334/4885CYP2C9 1904/4885CYP2C19 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.